Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin vs Sitagliptin in T2DM
NCT01984606Phase 3Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Planned start Jan 2015; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01984606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01984606.